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Dear Editor, 
 
We have read the paper by Fabiani et al. (Fabiani, et al 2018) investigating potential 
molecular mechanisms behind haematological improvement (HI) during iron chelation 
therapy (ICT) in patients with lower risk myelodysplastic syndrome (MDS) with great interest. 
Authors reported that neither patients’ characteristics (including baseline and follow-up 
ferritin concentrations), nor mutations in any of the specific genes frequently mutated in 
myeloid malignancies showed significant associations with the occurrence of HI during ICT. 
We would like to point out that haemochromatosis (HFE) gene mutations which are affecting 
significant proportion of MDS patients and increase the risk of iron accumulation in this 
context (De Souza, et al 2015, Lucijanic, et al 2016) were not assessed by the authors in the 
current study. 
 
Heterozygosity for HFE gene mutations is an equally common feature in both MDS patients 
and healthy population. Mutations show variable geographic distribution and affect up to one 
third of MDS patients when considering two most frequent mutations (C282Y, H63D) 
(Lucijanic, et al 2016). Although considered not to be directly implicated in the pathobiology 
of MDS and not to significantly affect iron accumulation in the general population (Burt, et al 
1998, Jackson, et al 2001, Rossi, et al 2001), heterozygosity for HFE gene mutations was 
shown to intensify iron overload in transfusion-dependent (De Souza, et al 2015) and 
accelerate iron accumulation in transfusion-independent MDS patients (Lucijanic, et al 2016). 
Most interestingly, HFE mutated patients seem to experience significantly shorter overall and 
leukaemia free survival (Lucijanic, et al 2016). Therefore, question emerges whether HFE 
mutated MDS patients might require lower thresholds to start chelation therapy and/or more 
intensive chelation to achieve response, but these issues have not been sufficiently 
investigated at the moment.  
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We congratulate the authors of the current work (Fabiani, et al 2018) on the valuable insight 
into the biology of MDS. However, mechanisms behind amelioration of iron overload and 
improvement in haematopoietic function still remain elusive. Since HFE gene mutations 
seem to significantly modulate iron metabolism in MDS, it would be very interesting to see 
whether they affect the odds of acquiring HI during ICT and how do they distribute among 
investigated somatic mutations. We hope that authors could provide such analysis. 
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